Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2020, Vol. 47 Issue (3): 320-323    DOI: 10.31083/j.ceog.2020.03.5254
Review | Next articles
Asymptomatic adnexal mass in postmenopausal women
A. Vatopoulou1, *(), A. Papanikolaou2
1First Department of Obstetrics and Gynecology, Medical School, Aristotle University Thessaloniki, Papageorgiou Hospital, Thessaloniki, Greece
2Second Department of Obstetrics and Gynecology, Medical School, Aristotle University Thessaloniki, Hippokration Hospital, Thessaloniki, Greece
Download:  PDF(158KB)  ( 310 ) Full text   ( 15 )
Export:  BibTeX | EndNote (RIS)      

The widespread use of vaginal ultrasound as an integral part of the gynecologic clinical examination in many countries has led to the unexpected finding of adnexal mass. The implications of the finding of an adnexal mass in an asymptomatic postmenopausal woman can be serious if it is malignant and is not excised, because ovarian cancer has an indolent course and when it becomes symptomatic it is often fatal. The aim of the present review is to discuss the evaluation and management of incidental adnexal masses in postmenopausal women. Despite careful evaluation with ultrasound and biomarkers, a small number of patients will remain without a conclusive diagnosis. It is our opinion, based on empirical evidence discussed here, that conservative therapy with observation can be safely applied in the majority of these patients.

Key words:  Adnexal mass      CA 125      Malignancy      Ultrasound     
Submitted:  09 May 2019      Accepted:  19 July 2019      Published:  15 June 2020     
*Corresponding Author(s):  ANASTASIA VATOPOULOU     E-mail:

Cite this article: 

A. Vatopoulou, A. Papanikolaou. Asymptomatic adnexal mass in postmenopausal women. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(3): 320-323.

URL:     OR

[1] van Nagell J.R., Jr., DePriest P.D., Ueland F.R., DeSimone C.P., Cooper A.L., McDonald J.M.: et al.: “Ovarian cancer screeningwith annual transvaginal sonography: findings of 25,000 women screened”. Cancer, 2007, 109, 1887-1896.
doi: 10.1002/cncr.22594 pmid: 17373668
[2] Menon U., Gentry-Maharaj A., Hallett R., Ryan A., Burnell M., Sharma A., et al.: “Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK collaborative trial of ovarian screening (UKCTOCS)”. Lancet Oncol., 2009, 10, 327-340.
doi: 10.1016/S1470-2045(09)70072-5 pmid: 19282241
[3] Valentin I., Skoog I., and Epstein E.: “Frequency and type of adnexal lesions in autopsy material from postmenopausal women: ultrasound study with histological correlation”. Ultrasound Obstet. Gynecol., 2003, 22, 284-289.
doi: 10.1002/uog.212 pmid: 12942502
[4] Pavlik E.J., Ueland F.R., Miller R.W., Ubellacker J.M., DeSimone C.P., Elder J., et al.: “Frequency and disposition of ovarian abnormalities followed with serial transvaginal ultrasonography”. Obstet. Gynecol., 2013, 122, 210-217.
doi: 10.1097/AOG.0b013e318298def5
[5] Henderson J.T., Webber E.M., Sawaya G.F.: “Screening for Ovarian Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force”. JAMA., 2018, 319, 595-606
doi: 10.1001/jama.2017.21421 pmid: 29450530
[6] Ferrazzi E., Zanetta G., Dordoni D., Berlanda N., Mezzopane R., Lissoni A.A.: “Transvaginal ultrasonographic characterization of ovarian masses: comparison of five scoring systems in a multicenter study”. Ultrasound Obstet. Gynecol., 1997, 10, 192-197.
doi: 10.1046/j.1469-0705.1997.10030192.x pmid: 9339526
[7] Ameye L., Valentin L., Testa A.C., Van Holsbeke C., Domali E., Van Huffel S., et al.: “A scoring system to differentiate malignant from benign masses in specific ultrasound-based subgroups of adnexal tumors”. Ultrasound Obstet. Gynecol., 2009, 33, 92-101.
doi: 10.1002/uog.6273 pmid: 19090501
[8] Nunes N., Yazbek J., Ambler G., Hoo W., Naftalin J., Jurkovic D.: “A prospective evaluation of the IOTA Logistic Regression Model (LR2) for the diagnosis of ovarian cancer”. Ultrasound Obstet. Gynecol., 2012, 40, 355-359.
doi: 10.1002/uog.11088 pmid: 22223587
[9] Valentin L., Ameye L., Savelli L., Fruscio R., Leone F.P.G., Czekierdowski A., et al.: “Adnexal masses difficult to classify as benign or malignant using subjective assessment of gray-scale and Doppler ultrasound findings: logistic regression models do not help”. Ultrasound Obstet. Gynecol., 2011, 38, 456-465.
doi: 10.1002/uog.9030 pmid: 21520475
[10] Kurjak A., Shalan H., Kupesic S., Kosuta D., Sosic A., Benic S., et al.: “An attempt to screen asymptomatic women for ovarian and endometrial cancer with transvaginal color and pulsed Doppler sonography”. J. Ultrasound. Med., 1994, 13, 295-301.
doi: 10.7863/jum.1994.13.4.295 pmid: 7932995
[11] Alcázar J.L., Mercé L.T., Manero M.G.: “Three-Dimensional Power Doppler Vascular Sampling”. J. Ultrasound. Med., 2005, 24, 689-696.
doi: 10.7863/jum.2005.24.5.689 pmid: 15840800
[12] Russell M.R., Graham C., D’Amato A., Gentry-Maharaj A., Ryan A., Kalsi J.K., et al.: “A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours”. Β. J. Cancer, 2017, 117, 666-674.
[13] Jacobs I., Bast R.C.: “The CA-125 tumor-associated antigen-a review of the literature”. Hum. Reprod., 1989, 4, 1-12.
doi: 10.1093/oxfordjournals.humrep.a136832 pmid: 2651469
[14] Medeiros L.R., Rosa D.D., da Rosa M.I., Bozzetti M.C.: “Accuracy of CA125 in the diagnosis of ovarian tumors: a quantitative systematic review”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2009, 142, 99-105.
doi: 10.1016/j.ejogrb.2008.08.011
[15] Holcomb K., Vucetic Z., Miller M.C., Knapp R.C.: “Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women”. Am. J. Obstet. Gynecol., 2011, 205, 358.e1 6.
doi: 10.1016/j.ajog.2011.05.017 pmid: 21722869
[16] Yurkovetsky Z., Skates S., Lomakin A., Nolen B., Pulsipher T., Modugno F., et al.: “Development of a multimarker assay for early detection of ovarian cancer”. J. Clin. Oncol., 2010, 28, 2159-2166.
doi: 10.1200/JCO.2008.19.2484 pmid: 20368574
[17] Bristow R.E., Smith A., Zhang Z., Chan D.W., Crutcher G., Fung E.T., et al.: “Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay”. Gynecol. Oncol., 2013, 128, 252-259.
doi: 10.1016/j.ygyno.2012.11.022
[18] Nolen B.M., Lokshin A.E.: “Biomarker testing for ovarian cancer: clinical utility of multiplex assays”. Mol. Diagn. Ther., 2013, 17, 139-146.
doi: 10.1007/s40291-013-0027-6
[19] Davies A.P., Jacobs I., Woolas R., Fish A., Oram D.: “The adnexal mass: benign or malignant? Evaluation of a risk of malignancy index”. Br. J. Obstet. Gynaecol., 1993, 100, 927-931.
doi: 10.1111/j.1471-0528.1993.tb15109.x pmid: 8217976
[20] Bailey J., Tailor A., Naik R., Lopes A., Godfrey K., Hatem H.M., et al.: “Risk of malignancy index for referral of ovarian cancer cases to a tertiary center: does it identify the correct cases?”. Int. J. Gynecol. Cancer, 2006, 16, 30-34.
doi: 10.1111/j.1525-1438.2006.00468.x pmid: 16515564
[21] American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. “Committee Opinion No. 477: “The role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer”. Obstet. Gynecol., 2011, 117, 742-746.
doi: 10.1097/AOG.0b013e31821477db pmid: 21343791
[22] Dearking A.C., Aletti G.D., McGree M.E., Weaver A.L.: “How relevant are ACOG and SGO Guidelines for referral of adnexal mass?”. Obstet. Gynecol., 2007, 110, 841-848.
doi: 10.1097/01.AOG.0000267198.25223.bc pmid: 17906018
[23] Moore R.G., Jabre-Raughley M., Brown A.K., Katina Robison M., Miller M.C., Allard W.J., et al.: “Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass”. Am. J. Obstet. Gynecol., 2010, 203, 228.e1 6.
doi: 10.1016/j.ajog.2010.03.043 pmid: 20471625
[24] Wei S., Li H., Zhang A.B.: “The diagnostic value of serum He4 and Ca 125 and Roma index in ovarian cancer”. Biomedical Reports, 2016, 5, 41-44.
doi: 10.3892/br.2016.682 pmid: 27347403
[25] Karlsen M.A., Hogdall E.V.S., Christensen I.J., Borgfeldt C., Kalapotharakos G., Zdrazilova-Dubska L., et al.: “A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer - An international multicenter study in women with an ovarian mass”. Gynecol. Oncol., 2015, 138, 640-646.
doi: 10.1016/j.ygyno.2015.06.021 pmid: 26086566
[26] Karlsen MA, Sandhu N, Hogdall C, Christensen Ib J., Nedergaard L., Lundvall L., et al.: “Evaluation of HE4, Ca125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass”. Gynecol. Oncol., 2012, 127, 379-383.
doi: 10.1016/j.ygyno.2012.07.106
[27] “Proceedings of the International Cancer Imaging Society (ICIS) 17th Annual Teaching Course”. Cancer Imaging, 2017, 17, 24.
doi: 10.1186/s40644-017-0126-4
[28] Gentry-Maharaj A., Taylor H., Kalsi J., Ryan A., Burnell M., Sharma A., et al.: “Validity of self-reported hysterectomy: a prospective cohort study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)”. BMJ. Open, 2014, 4, e004421.
[29] Shimada K., Matsumoto K., Mimura T., Ishikawa T., Munechika J., Ohgiya Y., et al.: “Ultrasound based logistic regression model LR2 versus magnetic resonance imaging for discriminating between benign and malignant adnexal masses: a prospective study”. Int. J. Clin. Oncol., 2018, 23, 514-521.
doi: 10.1007/s10147-017-1222-y pmid: 29236181
[30] Valentin L., Ameye L., Franchi D., Guerriero S., Jurkovic D.: “Risk of malignancy in unilocular cysts”. Ultrasound Obstet. Gynecol., 2013, 41, 80-89.
doi: 10.1002/uog.12308 pmid: 23001924
[31] Valentin L., Akrawi A.D.: “The natural history of adnexal cysts incidentally detected at transvaginal ultrasound examination in postmenopausal women”. Ultrasound Obstet. Gynecol., 2002, 20, 174-180.
doi: 10.1046/j.1469-0705.2002.00709.x pmid: 12153669
[32] Modesitt S.C., Pavlik E.J., Ueland F.R., DePriest P.D., Kryscio R.J., van Nagell J.R., Jr.: “Risk of malignancy in unilocular ovarian cystic tumors less than 10 centimeters in diameter”. Obstet. Gynecol., 2003, 102, 594-599.
doi: 10.1016/s0029-7844(03)00670-7 pmid: 12962948
[33] Sharma A, Gentry-Maharaj A, Burnell M, Fourkala E-O., Campbell S., Amso N., et al.: “Assessing the malignant potential of ovarian inclusion cysts in postmenopausal women within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a prospective cohort study”. BJOG., 2012, 119, 207-219.
doi: 10.1111/j.1471-0528.2011.03038.x pmid: 21762355
[34] Levine D., Brown D.L., Andreotti R.F., Benacerraf B., Benson C.B., Brewster W.R., et al.: “Management of asymptomatic ovarian andother adnexal cysts imaged at US: Society of Radiologists in Ultrasound Consensus Conference Statement”. Radiology, 2010, 256, 943-954.
doi: 10.1148/radiol.10100213 pmid: 20505067
[35] Suh-Burgmann E., Kinney W.: “The Value of Ultrasound Monitoring of Adnexal Masses for Early Detection of Ovarian Cancer”. Front. Oncol., 2016, 6, 25.
doi: 10.3389/fonc.2016.00025 pmid: 26904503
[36] Saunders B.A., Podzielinski I., Ware R.A., Goodrich S., DeSimone C.P., Ueland F.R., et al.: “Risk of malignancy in sonographically confirmed septated cystic ovarian tumors”. Gynecol. Oncol., 2010, 118, 278-282.
doi: 10.1016/j.ygyno.2010.05.013 pmid: 20554314
[37] Suh-Burgmann E., Hung Y.Y., Kinney W.: “Outcomes from ultrasound follow-up of small complex adnexal masses in women over 50”. Am. J. Obstet. Gynecol., 2014, 211, 623.e1-7
doi: 10.1016/j.ajog.2014.07.044
[38] “Management of suspected ovarian masses in premenopausal women”. Green-top Guideline No. 62, RCOG/BSGE Joint Guideline Royal College guidelines, 2011.
[39] Chang S.J., Bristow R.E.: “Evolution of surgical treatment paradigms for advanced stage ovarian cancer: redefining ‘optimal’ residual disease”. Gynecol. Oncol., 2012, 125, 483-492.
doi: 10.1016/j.ygyno.2012.02.024
[40] Fagotti A., Vizzielli G., De Iaco P., Surico D., Buda A., Mandatoe V.D., et al.: “A multicentric trial (Olympia-MITO 13) on the accuracy of laparoscopy to assess peritoneal spread in ovarian cancer”. Am. J. Obstet. Gynecol., 2013, 209, 462.
[1] C. Stenfelt, L. Ydenius, S. Lindberg, J. Spira, G. Edelstam. Effects of the colour and design of a new pelvic examination chair on comfort during gynaecological examination[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 556-559.
[2] S. Coremans, J. Muys, J. De Winter, H. De Raedemaecker, Y. Jacquemyn. Ultrasound by midwives in the postpartum period: feasibility, reproducibility and midwives’ perspectives[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(3): 348-354.
[3] D. Lu, D. Cao, Q. Zhao, X. Chen. Prenatal diagnosis and genetic counseling of mosaicism for chromosome t (7; 14) with a favorable outcome[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(3): 427-428.
[4] I.H. Kalelioglu, S.G. Erzincan, R. Has, A. Yuksel. Forehead and facial heights in Down syndrome and normal fetuses in the midtrimester of pregnancy[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(2): 220-227.
[5] C. Chan, J.W. Wang, C.W. Wang, C.W. Chang. A pitfall in ultrasonographic diagnosis–heterotopic cornual pregnancy initially misdiagnosed as leiomyoma[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(2): 296-298.
[6] C. Chollet, B. Andre, M. Voglimacci, A. Ghassani, O. Parant, P. Guerby. Perinatal outcomes of second trimester antenatal genital bleeding[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(1): 105-110.
[7] A.P. Londero, S. Visentin, L. Marin, M. C. Bongiorno, D. Visentin, S. Bertozzi, E. Cosmi, A Cagnacci, L. Driul. Second trimester prediction of small for gestational age and intrauterine growth restriction[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(1): 70-74.
[8] S.B. Cohen, M. Shapira, A. Baron, J. Bouaziz, R. Mashiach, M. Goldenberg, R. Orvieto. Ultrasonography-guided hysteroscopic tubal catheterization of proximally occluded tubes - reproductive outcomes[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(6): 872-875.
[9] G. Szabó, J. Rigó Jr.. Prenatal ultrasound diagnosis of abdominal pregnancy of ovarian origin[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(6): 977-979.
[10] P. Bielikova, R. Pilka, K. Huml, B. Melichar, H. Svebisova, J. Jankova, V. Prasil, I. Zambo, P. Janicek. Monophasic synovial sarcoma of the lower extremity at 20 weeks of pregnancy: a case report and review of the literature[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(6): 992-998.
[11] T. Murata, S. Suzuki, H. Kyozuka, M. Chishiki, H. Tanaka, K. Fujimori. Fetal primary volvulus with abnormal heart rate patterns on cardiotocography[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(6): 1003-1004.
[12] I. Korkontzelos, A. Vlachioti, P. Mavridou, A. Rapi, G. Tsanadis, T. Stefos. Heterotopic triplet pregnancy after in vitro fertilization and intracytoplasmatic sperm injection complicated with ovarian hyperstimulation syndrome single twin fetal demise and cervical incompetence: a successful obstetrical outcome[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(6): 1007-1010.
[13] K. Lee, S. Lee, H. N. Lee, H. Lim, I. J. Kim, I. Y. Park, M. J. Kim. Uterine necrosis following selective embolization for postpartum hemorrhage: report of four cases and review of literature[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(6): 1020-1025.
[14] N.N. Chavan, R. Deshmukh, N. Raj. An observational study on diagnosis and management of adnexal masses in pregnancy[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(4): 583-586.
[15] T. Mihailovic, B. Kuanova, M. Terzic, S. Terzic, N. Arsenovic. Bilateral pulmonary agenesis diagnosed in the 13th week of gestation - a case report and literature review[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(3): 479-481.
No Suggested Reading articles found!